HRP20211869T1 - Protutijela protiv faktora rasta živca i postupci za njihovu proizvodnju i uporabu - Google Patents
Protutijela protiv faktora rasta živca i postupci za njihovu proizvodnju i uporabu Download PDFInfo
- Publication number
- HRP20211869T1 HRP20211869T1 HRP20211869TT HRP20211869T HRP20211869T1 HR P20211869 T1 HRP20211869 T1 HR P20211869T1 HR P20211869T T HRP20211869T T HR P20211869TT HR P20211869 T HRP20211869 T HR P20211869T HR P20211869 T1 HRP20211869 T1 HR P20211869T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- binding fragment
- amino acid
- acid sequence
- Prior art date
Links
- 229940053128 nerve growth factor Drugs 0.000 title claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 230000027455 binding Effects 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 7
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 241000282324 Felis Species 0.000 claims 5
- 241000282326 Felis catus Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010036030 Polyarthritis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 102000015533 trkA Receptor Human genes 0.000 claims 1
- 108010064884 trkA Receptor Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/467—Igs with modifications in the FR-residues only
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
1. Protutijelo ili njegov fragment koji veže antigen, naznačeno time, da je sposobno za specifično vezanje na mačji faktor rasta živca (NGF) i za inhibiciju sposobnosti mačjeg faktora rasta živca (NGF) za vezanje na mačji p75 i/ili TrkA receptor NGF, pri čemu protutijelo ili njegov fragment koji veže antigen sadrži varijabilnu regiju lakog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 23, i varijabilnu regiju teškog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 22.
2. Protutijelo ili njegov fragment koji veže antigen prema patentnom zahtjevu 1, naznačeno time, da laki lanac sadrži aminokiselinski slijed SEQ ID NO: 25 ili aminokiselinski slijed koji je istovjetan s njim najmanje 85% , i time, da teški lanac sadrži aminokiselinski slijed SEQ ID NO: 24 ili aminokiselinski slijed koji je istovjetan s njim najmanje 85%.
3. Protutijelo ili njegov fragment koji veže antigen prema patentnom zahtjevu 1, naznačeno time, da sadrži konstantnu domenu teškog lanca odabranu ili modificiranu putem aminokiselinske supstitucije ili delecije tako, da navedena konstantna domena ne utječe na nizvodne efektorske funkcije.
4. Protutijelo ili njegov fragment koji veže antigen prema patentnom zahtjevu 3, naznačeno time, da protutijelo ima mačju konstantnu domenu tipa HC2.
5. Farmaceutski pripravak, naznačen time, da sadrži protutijelo ili njegov fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 4, zajedno s najmanje jednim farmaceutski prihvatljivim nosačem, pomoćnim sredstvom ili razrjeđivačem.
6. Protutijelo ili njegov fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time, da je za uporabu u liječenju stanja koje je povezano s boli, ili je za uporabu u liječenju, smanjivanju ili sprečavanju boli koja je povezana s imunosno posredovanim poliartritisom, osteoartritisom ili reumatoidnim artritisom, ili je za uporabu u liječenju tumora induciranog na proliferaciju putem NGF kod mačaka i stanja koja su povezana s time.
7. Komplet, naznačen time, da je za liječenje boli kod mačaka, ili je za liječenje stanja koje je povezano s boli, ili je za liječenje, smanjivanje ili sprečavanje boli koja je povezana s imunosno posredovanim poliartritisom, osteoartritisom ili reumatoidnim artritisom, ili je za liječenje tumora induciranog na proliferaciju putem NGF kod mačaka i stanja koja su povezana s time, pri čemu sadrži protutijelo ili njegov fragment koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 4, te uputstva za uporabu kompleta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161483488P | 2011-05-06 | 2011-05-06 | |
| US201161531439P | 2011-09-06 | 2011-09-06 | |
| EP18205428.8A EP3498732B1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211869T1 true HRP20211869T1 (hr) | 2022-03-04 |
Family
ID=79283336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211869TT HRP20211869T1 (hr) | 2011-05-06 | 2012-05-08 | Protutijela protiv faktora rasta živca i postupci za njihovu proizvodnju i uporabu |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4026845A1 (hr) |
| CY (1) | CY1124960T1 (hr) |
| DK (1) | DK3498732T3 (hr) |
| ES (1) | ES2905682T3 (hr) |
| FI (1) | FIC20220010I1 (hr) |
| FR (1) | FR22C1014I2 (hr) |
| HR (1) | HRP20211869T1 (hr) |
| HU (2) | HUE057288T2 (hr) |
| LT (2) | LT3498732T (hr) |
| NL (1) | NL301168I2 (hr) |
| NO (1) | NO2022008I1 (hr) |
| PL (1) | PL3498732T3 (hr) |
| PT (1) | PT3498732T (hr) |
| SI (1) | SI3498732T1 (hr) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| ATE448301T1 (de) | 2000-09-08 | 2009-11-15 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| WO2003060080A2 (en) * | 2001-12-21 | 2003-07-24 | Idexx Laboratories, Inc. | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US8337842B2 (en) * | 2008-09-04 | 2012-12-25 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| WO2012024650A2 (en) * | 2010-08-19 | 2012-02-23 | Abbott Laboratories | Anti-ngf antibodies and their use |
-
2012
- 2012-05-08 SI SI201231979T patent/SI3498732T1/sl unknown
- 2012-05-08 PL PL18205428T patent/PL3498732T3/pl unknown
- 2012-05-08 EP EP21207684.8A patent/EP4026845A1/en active Pending
- 2012-05-08 LT LTEP18205428.8T patent/LT3498732T/lt unknown
- 2012-05-08 ES ES18205428T patent/ES2905682T3/es active Active
- 2012-05-08 HR HRP20211869TT patent/HRP20211869T1/hr unknown
- 2012-05-08 DK DK18205428.8T patent/DK3498732T3/da active
- 2012-05-08 HU HUE18205428A patent/HUE057288T2/hu unknown
- 2012-05-08 PT PT182054288T patent/PT3498732T/pt unknown
-
2022
- 2022-02-02 CY CY20221100091T patent/CY1124960T1/el unknown
- 2022-03-30 LT LTPA2022005C patent/LTPA2022005I1/lt unknown
- 2022-04-04 NO NO2022008C patent/NO2022008I1/no unknown
- 2022-04-04 HU HUS2200012C patent/HUS2200012I1/hu unknown
- 2022-04-04 FI FIC20220010C patent/FIC20220010I1/fi unknown
- 2022-04-08 FR FR22C1014C patent/FR22C1014I2/fr active Active
- 2022-04-11 NL NL301168C patent/NL301168I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3498732T1 (sl) | 2022-04-29 |
| NL301168I1 (hr) | 2022-04-13 |
| NL301168I2 (nl) | 2022-11-24 |
| FIC20220010I1 (fi) | 2022-04-04 |
| FR22C1014I1 (fr) | 2022-06-17 |
| LTPA2022005I1 (hr) | 2022-04-25 |
| ES2905682T3 (es) | 2022-04-11 |
| LT3498732T (lt) | 2022-01-10 |
| EP4026845A1 (en) | 2022-07-13 |
| FR22C1014I2 (fr) | 2023-01-13 |
| HUE057288T2 (hu) | 2022-04-28 |
| HUS2200012I1 (hu) | 2022-05-28 |
| NO2022008I1 (no) | 2022-04-04 |
| PL3498732T3 (pl) | 2022-02-28 |
| DK3498732T3 (da) | 2022-01-17 |
| PT3498732T (pt) | 2022-02-02 |
| CY1124960T1 (el) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201156T1 (hr) | Zajednički laki lanci i postupci primjene | |
| HRP20201729T1 (hr) | Antitijela protiv aktivina a i njihova primjena | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20230237T1 (hr) | Anti-psma antitijela, bispecifične molekule za vezanje antigena koje vežu psma i cd3, i njihova uporaba | |
| HRP20201517T1 (hr) | Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123 | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| JP2019147801A5 (hr) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2014522236A5 (hr) | ||
| HRP20191999T1 (hr) | Monoklonska protutijela anti-faktora xi i postupci njihove uporabe | |
| FI2897981T3 (fi) | Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20161211T1 (hr) | Bispecifična antitijela protiv cd3-epsilon i bcma | |
| RU2020129387A (ru) | Антитела к pd-1 собак | |
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
| JP2017052784A5 (hr) | ||
| SI2771031T1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| RU2430111C3 (ru) | Молекулы антител с улучшенными свойствами | |
| HRP20231514T1 (hr) | Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| JP2015508757A5 (hr) | ||
| JP2015535828A5 (hr) |